News >

Personalized Immunotherapy Combinations on Horizon

Silas Inman @silasinman
Published: Thursday, Nov 08, 2018

Jason J. Luke, MD

Jason J. Luke, MD
Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment, according to a presentation by Jason Luke, MD, at the 36th Annual CFS®.

As single-agents, the immune checkpoint inhibitors have demonstrated utility across a broad spectrum of tumors. Additionally, some combinations of anti–PD-1 and anti–CTLA-4 inhibitors have gained approval along with immunotherapy and chemotherapy combinations. However, the recent failed phase III trial looking at pembrolizumab (Keytruda) and epacadostat has called research practices into question.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication